You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Globus Medical cut full-year 2026 revenue guidance to $3.09 billion, citing Nevro pressure and limited new-product contribution. Third-quarter revenue was $763.7 million, down 0.7%, while non-GAAP EPS was $1.23 and free cash flow reached a record $225 million.
Globus Medical reported nine-month net sales growth of 9.5%, while third-quarter sales fell 0.7%. Operating cash flow rose to $677,332 in thousands, and the company had no borrowings under its $400.0 million revolving facility.
Globus Medical reported third-quarter net sales of $763.7 million, down 0.7%, GAAP net income of $141.2 million and diluted EPS of $1.04. It increased its share repurchase authorization by $500 million and cut full-year 2026 revenue guidance to $3.09 billion.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Globus Medical delivered Q2 2026 sales of $789.6M (+5.9% reported), with U.S. spine up 7% and international spine up 14%, while reaffirming full-year revenue guidance at $3.18B-$3.22B and raising non-GAAP EPS guidance to $4.95-$5.05 from $4.70-$4.80.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 525.14M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA as a percentage of net sales non-GAAP | 33.9% | Six Months Ended June 30, 2026 | — |
| Adjusted Gross Profit non-GAAP | 1.07B | Six Months Ended June 30, 2026 | — |
| Adjusted Gross Profit % of Net Sales non-GAAP | 69.3% | Six Months Ended June 30, 2026 | — |
| Constant Currency Net Sales Growth non-GAAP | 14.5% | Six Months Ended June 30, 2026 | — |
| Free cash flow non-GAAP | 339.32M | Six Months Ended June 30, 2026 | — |
| Non-GAAP diluted earnings per share non-GAAP | $2.46 | Six Months Ended June 30, 2026 | — |
| Non-GAAP net income non-GAAP | 339.19M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GMED
this stock
Globus Medical Inc
|
$9.56B | -17.4% | +16.7% | 17.8 | 7.1% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Globus Medical reported third-quarter net sales of $763.7 million, down 0.7%, GAAP net income of $141.2 million and diluted EPS of $1.04. It increased its share repurchase authorization by $500 million and cut full-year 2026 revenue guidance to $3.09 billion.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GMED | +1.5% | -6.0% | -15.2% | -7.6% | -17.4% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -1.1% | -4.8% | -15.7% | -7.4% | -28.0% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
